Illinois SB1773 proposal would add xylazine as a Class III controlled substance and establish enumerated xylazine exemptions (Senate Committee Amendment No. 4)

Per the official ILGA bill record, SB1773 proposes to amend the Illinois Controlled Substances Act to add xylazine as a Class III controlled substance (effective date stated in the bill synopsis as January 1, 2026). The ILGA full-text for Senate Committee Amendment No. 4 includes a new Section 720 ILCS 570/309.1 (‘Xylazine exemptions’) specifying circumstances where xylazine ‘shall not be considered a controlled substance’ (e.g., certain FDA-approved/permitted animal-drug uses by licensed Illinois veterinarians, API manufacturing for approved animal drugs, use by certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinary supervision). Compliance teams should treat this as a pending change until enacted, but should assess potential impacts on controlled-substance controls and professional-use carve-outs for xylazine in Illinois if the bill becomes law.